Filing 2024 Q2 - Restatement compared to 2024 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Barbara Fiorini Due
General Counsel
Hellerup, Denmark
8/20/2024
Explanatory Note: This Amendment No. 1 restates the Form 13F Holdings Report filed by Novo Holdings A/S on August 14, 2024. This Amendment No. 1 (i) corrects data in the Information Table relating to the reported position in Evotec AG and Exscientia plc by removing the positions, (ii) corrects data in the Information Table relating to the reported position in Marqeta Inc by inserting 2419738 in Column 5 "VALUE" (iii) corrects data in the Information Table relating to the reported position in Viridian Therapeutics Inc by inserting 26020000 in Column 5 "VALUE", (iv) includes a position in Vanguard Index FDS, and (v) corrects the Report Summary by inserting $1,854,897,213 as the "Form 13F Information Table Values Total".
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.